0000950170-23-030757.txt : 20230629 0000950170-23-030757.hdr.sgml : 20230629 20230629161652 ACCESSION NUMBER: 0000950170-23-030757 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230627 FILED AS OF DATE: 20230629 DATE AS OF CHANGE: 20230629 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Haviland Kate CENTRAL INDEX KEY: 0001663022 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38978 FILM NUMBER: 231057599 MAIL ADDRESS: STREET 1: BLUEPRINT MEDICINES CORPORATION STREET 2: 38 SIDNEY STREET, SUITE 200 CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Fulcrum Therapeutics, Inc. CENTRAL INDEX KEY: 0001680581 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474839948 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 26 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-651-8851 MAIL ADDRESS: STREET 1: 26 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 ownership.xml 4 X0407 4 2023-06-27 false 0001680581 Fulcrum Therapeutics, Inc. FULC 0001663022 Haviland Kate C/O FULCRUM THERAPEUTICS, INC. 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 true false false false false Stock Option (right to buy) 3.16 2023-06-27 4 A false 30000 0.00 A 2033-06-26 Common Stock 30000 30000 D This option was granted on June 27, 2023 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service. /s/ Greg Tourangeau, as attorney-in-fact for Kate Haviland 2023-06-29